- Home
- COUR vs JANX Comparison
COUR vs JANX Comparison
Compare COUR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COUR
- JANX
- Stock Information
- Founded
- COUR 2012
- JANX 2017
- Country
- COUR United States
- JANX United States
- Employees
- COUR N/A
- JANX N/A
- Industry
- COUR Computer Software: Prepackaged Software
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- COUR Technology
- JANX Health Care
- Exchange
- COUR Nasdaq
- JANX Nasdaq
- Market Cap
- COUR 1.3B
- JANX 1.5B
- IPO Year
- COUR 2021
- JANX 2021
- Fundamental
- Price
- COUR $8.93
- JANX $26.38
- Analyst Decision
- COUR Hold
- JANX Strong Buy
- Analyst Count
- COUR 13
- JANX 8
- Target Price
- COUR $10.52
- JANX $90.63
- AVG Volume (30 Days)
- COUR 1.8M
- JANX 790.0K
- Earning Date
- COUR 07-24-2025
- JANX 08-06-2025
- Dividend Yield
- COUR N/A
- JANX N/A
- EPS Growth
- COUR N/A
- JANX N/A
- EPS
- COUR N/A
- JANX N/A
- Revenue
- COUR $704,874,000.00
- JANX $9,336,000.00
- Revenue This Year
- COUR $6.70
- JANX N/A
- Revenue Next Year
- COUR $4.88
- JANX $1,470.82
- P/E Ratio
- COUR N/A
- JANX N/A
- Revenue Growth
- COUR 7.25
- JANX 28.12
- 52 Week Low
- COUR $5.76
- JANX $22.48
- 52 Week High
- COUR $11.74
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- COUR 58.87
- JANX 56.48
- Support Level
- COUR $8.47
- JANX $25.81
- Resistance Level
- COUR $8.77
- JANX $28.39
- Average True Range (ATR)
- COUR 0.28
- JANX 1.20
- MACD
- COUR 0.05
- JANX 0.25
- Stochastic Oscillator
- COUR 90.87
- JANX 61.75
About COUR Coursera Inc.
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.